- Home
- GFAI vs SABS Comparison
GFAI vs SABS Comparison
Compare GFAI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFAI
- SABS
- Stock Information
- Founded
- GFAI 2018
- SABS 2014
- Country
- GFAI Singapore
- SABS United States
- Employees
- GFAI N/A
- SABS N/A
- Industry
- GFAI Diversified Commercial Services
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- GFAI Consumer Discretionary
- SABS Health Care
- Exchange
- GFAI Nasdaq
- SABS Nasdaq
- Market Cap
- GFAI 20.7M
- SABS 19.0M
- IPO Year
- GFAI N/A
- SABS N/A
- Fundamental
- Price
- GFAI $1.03
- SABS $1.48
- Analyst Decision
- GFAI Strong Buy
- SABS Strong Buy
- Analyst Count
- GFAI 2
- SABS 5
- Target Price
- GFAI $6.75
- SABS $12.40
- AVG Volume (30 Days)
- GFAI 370.3K
- SABS 37.8K
- Earning Date
- GFAI 04-28-2025
- SABS 05-19-2025
- Dividend Yield
- GFAI N/A
- SABS N/A
- EPS Growth
- GFAI N/A
- SABS N/A
- EPS
- GFAI N/A
- SABS N/A
- Revenue
- GFAI $35,841,743.00
- SABS $1,512,723.00
- Revenue This Year
- GFAI $0.37
- SABS N/A
- Revenue Next Year
- GFAI $5.60
- SABS N/A
- P/E Ratio
- GFAI N/A
- SABS N/A
- Revenue Growth
- GFAI 1.78
- SABS N/A
- 52 Week Low
- GFAI $0.94
- SABS $1.45
- 52 Week High
- GFAI $4.20
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- GFAI 39.69
- SABS 37.64
- Support Level
- GFAI $1.08
- SABS $1.53
- Resistance Level
- GFAI $1.25
- SABS $1.80
- Average True Range (ATR)
- GFAI 0.07
- SABS 0.16
- MACD
- GFAI 0.02
- SABS 0.03
- Stochastic Oscillator
- GFAI 20.86
- SABS 7.14
About GFAI Guardforce AI Co. Limited
Guardforce AI Co Ltd is a provider of cash solutions and cash handling services located in Thailand. The company engages in the cash logistics business, and its services include cash-in-transit, or CIT, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions (cash deposit management and express cash service). Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.